Biotech catalyst, news and analysis PDUFA tracker
Intraday Charts and Alerts
Ultra-microcap deep dive on Actelis Networks after a series of transportation, utility and carrier orders, reverse split and financing moves. Focus on the core technology, recent contracts, balance sheet stress and the asymmetry between operational progress and capital structure risk.
The company says this is its first successful net-based interception at that speed, positioning DefendAir for “on-the-move” protection against fast FPV-style threats and other tactical drones.
Jiade is a micro-cap education-support company listed on Nasdaq, best known for providing tutoring and training services for adult and vocational education in China. A strategic cooperation with a South Korea–based AI education brand adds an international angle, but the story still sits at the intersection of cross-border ambitions, regulatory risk and the harsh math of small-cap liquidity.
Cyngn (ticker CYN) sits in a corner of the market that many traders only notice when the tape goes vertical: micro-cap industrial autonomy. This is not a classical biotech binary, not a cash-generating SaaS giant, and definitely not a clean “AI story” with nine-figure revenues. It is a company trying to turn a fairly sophisticated autonomy stack into a repeatable, contract-driven business in forklifts, tuggers and other industrial vehicles – while burning real money and living under the constant threat of dilution.
Real-time news feeds (RTTNews, MarketScreener, StockTitan, QuiverQuant) and broker dashboards show VIVS up roughly +70–100% in pre-market trading on 30 January 2026, with pre-market prices around 3.0 USD and, in some snapshots, higher peaks depending on the exact timestamp. Versus a previous close of 1.70 USD, this is a classic microcap “gap & squeeze” setting, driven by a mix of genuine news and positioning on a very small float.
Jeffs’ Brands Ltd is a tiny Israeli micro-cap originally built around a data-driven Amazon FBA portfolio. That legacy business is still there: roughly $13.7M revenue in FY2024 against a net loss of about $7.8M, with a very small equity value and high operating leverage. The last twelve months have been brutal for long-term holders, with a price trajectory closer to a ski slope than a growth story.
